our_people1.jpg

Peter Gray

Chairman

  • R
  • N

Peter Gray

Chairman

Peter Gray (64) is Chairman and non-executive director of UDG Healthcare plc. Peter formerly held senior executive positions in a number of Irish public companies, the most recent being that of Vice Chairman and Chief Executive of ICON plc, the Irish based multinational pharmaceutical development services company.

External Appointments: Peter is currently a non-executive director of Jazz Pharmaceuticals plc and a director of two venture capital backed private companies.

Peter Gray sits on the following committees:

Brendan-McAtamney.jpg

Brendan McAtamney

Chief Executive Officer

Brendan McAtamney

Chief Executive Officer

Brendan McAtamney (56) was appointed Group Chief Executive Officer on 2 February 2016, having previously served as the Group’s Chief Operating Officer since 1 September 2013. Before joining UDG Healthcare, Brendan held various senior management positions with Abbott, latterly as Vice President Commercial and Corporate Officer within the Established Pharmaceuticals division.

External Appointments:  Brendan is currently a non-executive director of Scapa Group plc.

Nigel-Clerkin-May2018.jpg

Nigel Clerkin

Chief Financial Officer

Nigel Clerkin

Chief Financial Officer

Nigel Clerkin (45) joined UDG Healthcare plc as Chief Financial Officer on 1 May 2018. Prior to this, Nigel held the position of CFO with ConvaTec Group plc where he worked for three years. Before this, he worked with Elan Corporation plc both in the US and Europe, holding the position of Executive Vice President and CFO. Nigel started his career at KPMG and is a fellow of the Institute of Chartered Accountants of Ireland.

Chris-Brinsmead.jpg

Chris Brinsmead CBE

Non–Executive Director

  • R
  • R
  • N

Chris Brinsmead CBE

Non–Executive Director

Chris Brinsmead CBE (59) was formerly Chairman of AstraZeneca Pharmaceuticals UK, President of AstraZeneca UK and Ireland and President of the Association of the British Pharmaceutical Industry (ABPI). Chris succeeded Philip Toomey as Senior Independent Director on 1 July 2017.

External Appointments: Chris is currently a non-executive director of the Wesleyan Assurance Society and Collagen Solutions plc. Chris will join Consort Medical plc as a non-executive director in February 2019, and will become Chairman in April 2019.

Chris Brinsmead CBE sits on the following committees:

Linda-Wilding.jpg

Linda Wilding

Non-Executive Director

  • A
  • R
  • N

Linda Wilding

Non-Executive Director

Linda Wilding’s (59) career includes 12 years at Mercury Asset Management where she held the position of Managing Director in the Private Equity division. Prior to this, Linda qualified as a chartered accountant while working with Ernst & Young.

External Appointments: Linda is currently a non-executive director of Electra Private Equity plc and Skagen Conscious Capital Limited.

Linda Wilding sits on the following committees:

Myles-Lee-April-2017teal.jpg (1)

Myles Lee

Senior Independent Director

  • A
  • N

Myles Lee

Senior Independent Director

Myles (65) was Group Chief Executive of CRH plc, a FTSE 100 and Fortune 500 company, prior to retiring in December 2013. With more than 30 years’ experience at senior financial and managerial level, Myles has extensive global experience in management, M&A and finance. He is a qualified civil engineer and a Fellow of the Institute of Chartered Accountants in Ireland.

External Appointments: Myles is currently a non-executive director of both Ingersoll-Rand Inc. and Babcock International Group plc.

Myles Lee sits on the following committees:

Lisa-Ricci.jpg

Lisa Ricciardi

Non-Executive Director

  • R
  • R

Lisa Ricciardi

Non-Executive Director

Lisa Ricciardi (58) is currently the Chief Executive Officer of Suono Bio Inc. Prior to this, Lisa was Senior Vice President of Foundation Medicine, Inc. and formally Senior Vice President of US and International Business Development at Medco Health Solutions. Lisa also held multiple senior roles in Pfizer, first in operations then leading business development for over a decade.

External Appointments: Lisa is currently Chief Executive Officer of Suono Bio Inc. and a Member of the Advisory Council for Humania Capital (DIFC) Limited.


 

Lisa Ricciardi sits on the following committees:

miller-rich-nancy.jpg

Nancy Miller-Rich

NON-EXECUTIVE DIRECTOR

  • R

Nancy Miller-Rich

NON-EXECUTIVE DIRECTOR

Nancy Miller-Rich (59) was formerly Senior Vice-President, Business Development & Licensing, Strategy and Commercial Support for Global Human Health at MSD, known as Merck in the US and Canada, until her retirement in September 2017. With more than 35 years’ experience in the healthcare industry, Nancy’s background includes roles in sales, marketing and business development for MSD, Schering-Plough, Sandoz (now Novartis) and Sterling Drug.

External Appointments: Nancy is an adviser with the Gerson Lehrman Group, a director of Intercept Pharmaceuticals Inc and Executive Chairman of Altum Pharma.

Nancy Miller-Rich sits on the following committees:

Chris-Corbin.jpg

Chris Corbin

Non-Executive Director

Chris Corbin

Non-Executive Director

Chris Corbin (63) retired as executive Chairman of the Ashfield division in July 2018 but has remained on the board in a non-executive director capacity. Chris founded Ashfield Healthcare Limited. Prior to this he held sales management positions with Parke Davis, Fisons, Astra and May & Baker. Chris was formerly Patron for SETPOINT Leicestershire, Chairman of Leicestershire Business Awards and a member of Derbyshire Magistrates Bench.

External Appointments: Chris is a director of a number of privately held companies.

Erik-Van-Snippenberg.jpg

Erik Van Snippenberg

Non-Executive Director

  • A

Erik Van Snippenberg

Non-Executive Director

Erik Van Snippenberg (54) spent almost 30 years with GlaxoSmithKline (GSK). More recently, Erik held the position of Senior Vice President and Area Head for Europe and Canada and was a member of GSK’s Global Pharmaceutical Management Team. Prior to this, Erik held a number of senior executive roles such as Senior Vice-President and Director of UK and Ireland.

External Appointments: Erik is currently a non-executive director of Eurovite Group.

Erik Van Snippenberg sits on the following committees:

Peter Chambre.jpg (1)

Peter Chambre

NON-EXECUTIVE DIRECTOR

  • R

Peter Chambre

NON-EXECUTIVE DIRECTOR

Peter Chambre has held senior positions in the pharmaceutical and life sciences sectors and has been a director of a number of international public and private companies. Prior to this, Peter held the position of Chief Executive Officer of Cambridge Antibody Group plc until 2006, and before that the roles of Chief Operating Officer of Celera Genomics Group and Chief Executive Officer of Bespak plc (now Consort Medical plc). More recently, Peter was a non-executive director of Spectris plc until December 2016, and of Touchstone Innovations plc until January 2017, both publicly-quoted companies.


External Appointments: Peter is currently Chairman of Immatics Biotechnologies GmbH, a clinical stage cancer immunotherapy company based in Germany and the United States. He also is a Trustee of Cancer Research UK since 2016 and has also chaired Cancer Research Technology, the charity's commercialisation division since 2011.

Peter Chambre sits on the following committees:

Shane Cooke resize.jpg

Shane Cooke

NON-EXECUTIVE DIRECTOR

  • R

Shane Cooke

NON-EXECUTIVE DIRECTOR

Shane Cooke has extensive experience in the pharmaceutical and life sciences sectors in both Europe and the United States and is currently a non-executive director of NASDAQ-listed Alkermes plc, having previously held the position of President from September 2011 until his retirement in March 2018.  Prior to this, Shane spent 10 years as Chief Financial Officer of Elan Corporation plc from 2001 and from 2007 he also was Head of Elan Drug Technologies. Prior to Elan he held the role of Chief Executive Officer of Pembroke Capital Ltd, an aviation leasing company of which he was a founder.  


External Appointments: Shane currently serves as a non-executive director on the board of Prothena Corporation plc and Endo International plc, both publicly-quoted companies.

Shane Cooke sits on the following committees: